ArticlePloS one2026
Psychiatric polypharmacy in adult patients at the only referral psychiatric institute in Botswana: A cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite growing acceptance in some clinical settings, its risks necessitate caution due to adverse effects, drug interactions, and poor adherence. We aimed to find the prevalence, patterns, and predictors of psychiatric polypharmacy among adults at Sbrana Psychiatric Hospital (SPH) in Lobatse, Botswana.
methodsThis cross-sectional study involved the collection of demographic and clinical data via interviews and medical records from 300 participants at SPH, which were subsequently analyzed using multivariable logistic regression.
resultsThe mean age of participants was 36.5 years (SD 12.1), and they were predominantly male (55.3%). The overall prevalence of psychiatric polypharmacy was 49.7%, with the most prevalent subtype being multi-class polypharmacy (79.2%). Inpatients (Adjusted Odds Ratio [AOR] = 5.00; 95% Confidence Interval [CI]: 2.70,9.25), individuals with substance use disorder (AOR = 4.60; 95% CI: 1.18, 1.18,17.86), and those diagnosed with bipolar mood disorder (AOR = 2.67; 95% CI: 1.49,4.80) exhibited significant associations with psychiatric polypharmacy.
conclusionsPsychiatric polypharmacy is common in this group, mostly due to bipolar disorder or substance use disorders. It is crucial to identify high-risk patients for reviews and to train clinicians in rational prescribing to improve medication use and minimize risks in Botswana.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.